Therapeutic drug monitoring versus Bayesian AUC-based dosing for vancomycin in routine practice: a cost–benefit analysis
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf011 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Barbara O M Claus und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium. Hauptthemen laut MEDLINE: Vancomycin, Drug Monitoring, Anti-Bacterial Agents, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
AUC-based dosing with validated Bayesian software is recommended as a good approach to guide bedside vancomycin dosing.
Objectives
To compare treatment and vancomycin-associated acute kidney injury (AKI) costs between Bayesian AUC-based dosing and conventional therapeutic drug monitoring (TDM) using steady-state plasma concentrations of vancomycin administered as continuous infusion in hospitalized non-critically ill patients with severe Gram-positive infection.
Methods
A cost–benefit analysis presented as a return on investment (ROI) analysis from a hospital perspective was conducted using a decision tree model (TDM versus AUC-based dosing) to simulate treatment cost (personnel, serum sampling and drug cost), vancomycin-associated AKI risk and cost up to 14 days. ROI was calculated against AUC-based software cost. One-way and probabilistic sensitivity analyses (respectively OWSA and PSA) were performed to check for robustness.
Results
In base case, an overall cost per patient of €621.0 with TDM and €543.6 with AUC-based dosing resulted in a treatment saving of €77.4 per patient when applying AUC-based dosing. This saving against the software cost (€26.9/patient) generated an ROI per patient of €1.9 per invested € in software [€1.9 (95% CI 1.6–2.2) in PSA]. Enrolling 900 AUC-based dosed patients annually translated to a net saving of €45 469. Software break-even was reached after 313 patients. In OWSA, a higher AKI risk with TDM strongly contributed to a positive ROI.
Conclusions
AUC-based dosing appeared a cost-saving strategy compared with conventional TDM when applying base-case settings of vancomycin-associated AKI risk, treatment and AKI costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
- Department of Pharmaceutical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
- Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
- Department of Basic and Applied Medical Sciences, Faculty of Medicine and Health Sciences, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
- Department of Pediatric Intensive Care, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
ORCID-Profile: Delphine De Smedt
Zitieren
APA
Claus, B. O. M., De Smedt, D., & De Cock, P. A. (2025). Therapeutic drug monitoring versus Bayesian AUC-based dosing for vancomycin in routine practice: a cost–benefit analysis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf011
Vancouver
Claus BOM, De Smedt D, De Cock PA. Therapeutic drug monitoring versus Bayesian AUC-based dosing for vancomycin in routine practice: a cost–benefit analysis. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf011
BibTeX
@article{Claus2025,
author = {Claus, Barbara O M and De Smedt, Delphine and De Cock, Pieter A},
title = {Therapeutic drug monitoring versus Bayesian AUC-based dosing for vancomycin in routine practice: a cost–benefit analysis},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf011}
}
EUVIMED